On October 27, 2022, Wolf Popper filed a stipulation of settlement with the Delaware Court of Chancery, proposing to settle claims of former Asterias Biotherapeutics shareholders related to the 2019 merger between Asterias and BioTime, Inc. (now known as Lineage Cell Therapeutics, Inc.).
The $10.65 million proposed settlement consists of up to $3.53 million of Lineage Cell Therapeutics stock with the remainder to be paid in cash. Vice Chancellor Lori W. Will will now review the settlement.